The Prognostic Significance of Tumor Angiogenesis and Expression of Vascular Endothelial Growth Factor in Papillary Carcinomas of the Thyroid Gland

갑상선 유두상 암종에서 종양혈관형성 및 혈관내피성장인자 발현의 예후인자적 의의

  • Kang Hun-Dae (Department of Surgery, Inje University College of Medicine) ;
  • Kim Seong-Bae (Department of Surgery, Gupo Sung Sim Hospital) ;
  • Kim Tae-Hyun (Department of Surgery, Inje University College of Medicine) ;
  • Oh Sang-Hoon (Department of Surgery, Inje University College of Medicine) ;
  • Yoon Hye-Kyong (Department of Pathology, Inje University College of Medicine) ;
  • Kim Sang-Hyo (Department of Surgery, Inje University College of Medicine)
  • 강헌대 (인제대학교 의과대학 부산 백병원 외과학교실) ;
  • 김성배 (구포성심병원 외과) ;
  • 김태현 (인제대학교 의과대학 부산 백병원 외과학교실) ;
  • 오상훈 (인제대학교 의과대학 부산 백병원 외과학교실) ;
  • 윤혜경 (인제대학교 의과대학 병리과학교실) ;
  • 김상효 (인제대학교 의과대학 부산 백병원 외과학교실)
  • Published : 2004.11.01

Abstract

Objectives: The purpose of this study was to evaluate for prognostic significance of VEGF expression and tumor angiogenesis in papillary carcinomas of the thyroid. Materials and Methods: The materials were 79 cases of papillary thyroid carcinomas, and age, sex, tumor size, multiplicity of tumor, capsular invasion, lymph node metastasis, recurrence, TNM stage, DeGroot stage and AMES scale were evaluated. An immunohistochemical stains for CD 34 to estimate microvessel density (MVD), and VEGF were done. MVD was defined as an average count of vessels per ${\times}400$ power field in the most vascularized area. VEGF expression was interpreted as 1+ and 2+ according to staining intensity and percentages of positive cells. Results: Mean score of MVD was $39.7{\pm}16.9.$ MVD were significantly higher in cases with capsular invasion (p=0.0001), lymph node metastasis (p=0.0001), TNM stage III (p=0.0022), DeGroot stage III (p=0.0163) and high risk group by AMES scale (p=0.0001). VEGF 2+ expression rate was significantly increased in cases with capsular invasion and lymph node metastasis (p=0.0006, p=0.0013), and in cases with TNM stage III, DeGroot stage III and high risk group by AMES scale (p=0.0236, p=0.0003, p=0.0293). In VEGF 2 + expression group, MVD was significantly higher than in VEGF 1 + group (p=0.0008), and MVD showed positive relation to VEGF 2 + expression (r=0.4616). Conclusion: VEGF expression and high MVD were significantly correlated to capsular invasion, lymph node metastasis, TNM stage III, DeGroot stage III and high risk group by AMES scale. The expression of VEGF and high MVD could be considered to be one of prognostic factor in papillary thyroid carcinomas.

Keywords

References

  1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31 https://doi.org/10.1038/nm0195-27
  2. Folkman J, Shing Y: Angiogenesis. J BioI Chem. 1992;267:10931-10934
  3. Folkman J, Klangsburn M: Angiogenetic factors. Science. 1987;235:442-447 https://doi.org/10.1126/science.2432664
  4. Cotran RS, Kumar V, Collins T: Robbins pathologic basis of disease. 6th ed. Philadelphia: WB Saunders, 1999:301-302
  5. Bremer GL, Tiebosch AT, van der Putten HW, Schouten HJ, de Haan J, Arends JW: Tumor angiogenesis: an independent prognostic parameter in cervical cancer. Am J Obstet Gynecol. 1996;174:126-131 https://doi.org/10.1016/S0002-9378(96)70384-8
  6. Shibuya M: Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res. 1995;67:281-316 https://doi.org/10.1016/S0065-230X(08)60716-2
  7. Jeong SJ, Park SJ, Cha SJ, et al: VEGF expression and MVD in ductal carcinoma of breast. J Korean Cancer Assc. 1999;31:1168-1678
  8. Cady B, Rossi R: An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953
  9. Park CS, Chung WY, Sub JH, Kim HG: An immunohistochemical study of tumar angiogenesity and EMA reactivity in papillary thyroid carcinoma. J Korean Cancer Assoc. 1997;29:454-465
  10. Jeon MY,Sol MY, Park KS, Yoon HK: Microvessel density and vascular endothelial growth factor expression in invasive breast carcinomas. Korean J Pathol. 2000;34:138-144
  11. Cohn K, Backdahl M, Forsslund G, Auer G, Lundell G, Lowhagen T: Prognostic value of nuclear DNA content in papillary thyroid carcinoma. World J Surg. 1984;8:474-480 https://doi.org/10.1007/BF01654917
  12. Basolo F, Pinchera, Fugazzola L, et al: Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. Eur J Cancer. 1994;30:171-174 https://doi.org/10.1016/0959-8049(94)90081-7
  13. Ryu KS, Sol MY, Yim HE, Kim MW: Correlations of the aggressiveness of thyroid cancer with microvessel density, expression of vascular endothelial growth factor and its receptors. J Korean Surg Soc. 2000;58:205-212
  14. Bosari S, Lee AK, Delellis RA, Wiley BD, Heatler GJ, Silveman ML: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum PathoI 1992;23:755-761 https://doi.org/10.1016/0046-8177(92)90344-3
  15. Akslen LA, Livolsi VA: Increased angiogenesis in papillary carcinoma but lack of prognostic importance. Hum Pathol. 2000;31:439-442 https://doi.org/10.1053/1-ip.2000.6548
  16. Lennard CM, Patel A, Wilson J, et al: Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery. 2001;129:552-558 https://doi.org/10.1067/msy.2001.112592
  17. Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F: Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol. 1996;9:636-641
  18. Maeda K, Chung YS, Ogawa Y, et al: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-863 https://doi.org/10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A
  19. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964-3968
  20. Eisma RJ, Spiro JD, Kreutzer DL: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg. 1997;174:513-517 https://doi.org/10.1016/S0002-9610(97)00166-9
  21. Soh EY, Sobhi SA, Wong MG, et al: Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery. 1996;120:944-947. https://doi.org/10.1016/S0039-6060(96)80038-9
  22. Klein M, Picard E, Vignaud JM, et al: Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol. 1999;161:41-49 https://doi.org/10.1677/joe.0.1610041